Kennedy announced in a statement Tuesday that 22 projects, totaling $500 million, to develop vaccines using mRNA technology ...

Pfizer (PFE), and Sanofi (SNY) drew increased attention on Tuesday as traders reacted to the U.S. government’s move to halt future mRNA vaccine development under the Biomedical Advanced Research and ...

In a note to employees on Thursday, Moderna Inc. said it was laying off about 10% of its global workforce as part of the ...

Discover key takeaways from Moderna's Q2 2025 earnings call, including FDA approvals, cost reductions, pipeline strategies, and financial updates.

Nevertheless, Moderna has lowered its revenue guidance for the year by $300 million. The company now expects to generate ...

The layoffs are part of an ongoing effort to reduce operating costs amid government and competitive challenges to its vaccine ...

Moderna topped Wall Street sales expectations and reported a lower-than-expected second-quarter loss on Friday, driven by ...

Moderna’s second-quarter sales fell less sharply than Wall Street expected as it works to expand its offerings amid weakening ...

In a memo, CEO Stéphane Bancel said the job cuts are needed to align the struggling vaccine maker’s cost structure with the ...

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based combination shot that targets both influenza and COVID-19. Now, the entire ...

Moderna's COVID-19 vaccine has received full approval from the U.S. Food and Drug Administration (FDA) for use in children with medical conditions that put them at higher risk of severe illness.